BRISTOL-MYERS SQUIBB COMPANY Restricted Cash and Cash Equivalents, Noncurrent
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Restricted Cash and Cash Equivalents, Noncurrent of $54.00 million as of 2023-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Restricted Cash and Cash Equivalent, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2024-10-31
- 2023-09-30: Restricted Cash and Cash Equivalents, Noncurrent $54.00M.
- 2023-06-30: Restricted Cash and Cash Equivalents, Noncurrent $53.00M.
- 2023-03-31: Restricted Cash and Cash Equivalents, Noncurrent $53.00M.
- 2022-09-30: Restricted Cash and Cash Equivalents, Noncurrent $223.00M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2023-09-30 | $54.00M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $53.00M 10-Q · filed 2024-07-26 |
| 2023-03-31 | $53.00M 10-Q · filed 2024-04-25 |
| 2022-09-30 | $223.00M 10-Q · filed 2023-10-26 |
| 2022-06-30 | $210.00M 10-Q · filed 2023-07-27 |
| 2022-03-31 | $210.00M 10-Q · filed 2023-04-27 |
| 2021-09-30 | $339.00M 10-Q · filed 2022-10-26 |
| 2021-06-30 | $373.00M 10-Q · filed 2022-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |